Advertisement
U.S. markets close in 2 hours 21 minutes
  • S&P 500

    5,129.75
    +33.48 (+0.66%)
     
  • Dow 30

    39,052.33
    +55.94 (+0.14%)
     
  • Nasdaq

    16,267.98
    +176.06 (+1.09%)
     
  • Russell 2000

    2,074.48
    +19.64 (+0.96%)
     
  • Crude Oil

    80.09
    +1.83 (+2.34%)
     
  • Gold

    2,095.20
    +40.50 (+1.97%)
     
  • Silver

    23.38
    +0.49 (+2.16%)
     
  • EUR/USD

    1.0842
    +0.0035 (+0.33%)
     
  • 10-Yr Bond

    4.1990
    -0.0530 (-1.25%)
     
  • GBP/USD

    1.2660
    +0.0033 (+0.26%)
     
  • USD/JPY

    150.1510
    +0.1670 (+0.11%)
     
  • Bitcoin USD

    62,365.63
    +1,690.76 (+2.79%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,682.50
    +52.48 (+0.69%)
     
  • Nikkei 225

    39,910.82
    +744.63 (+1.90%)
     

Returns On Capital At Medinex (Catalist:OTX) Paint A Concerning Picture

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expanding base of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. Although, when we looked at Medinex (Catalist:OTX), it didn't seem to tick all of these boxes.

What Is Return On Capital Employed (ROCE)?

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. Analysts use this formula to calculate it for Medinex:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.051 = S$943k ÷ (S$21m - S$2.4m) (Based on the trailing twelve months to September 2023).

So, Medinex has an ROCE of 5.1%. In absolute terms, that's a low return and it also under-performs the Healthcare industry average of 8.6%.

View our latest analysis for Medinex

roce
roce

While the past is not representative of the future, it can be helpful to know how a company has performed historically, which is why we have this chart above. If you want to delve into the historical earnings, revenue and cash flow of Medinex, check out these free graphs here.

The Trend Of ROCE

In terms of Medinex's historical ROCE movements, the trend isn't fantastic. To be more specific, ROCE has fallen from 14% over the last five years. And considering revenue has dropped while employing more capital, we'd be cautious. If this were to continue, you might be looking at a company that is trying to reinvest for growth but is actually losing market share since sales haven't increased.

What We Can Learn From Medinex's ROCE

We're a bit apprehensive about Medinex because despite more capital being deployed in the business, returns on that capital and sales have both fallen. Investors must expect better things on the horizon though because the stock has risen 12% in the last five years. Regardless, we don't like the trends as they are and if they persist, we think you might find better investments elsewhere.

On a final note, we found 4 warning signs for Medinex (2 are concerning) you should be aware of.

If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Advertisement